The above-mentioned lines of evidence and geographical variation in the prevalence of gene mutations indicate that studying the status of KRAS, DDR2, and TP53 may have important implications for diagnosis, prognosis, cancer recurrence prevention, and designing clinical trials and targeted therapies for Iranian population with lung cancer. This evidence concerns the gene KRAS and lung cancer.